We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


IDT Signs Contract to Supply Research Councils UK with Custom Oligonucleotides

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "IDT Signs Contract to Supply Research Councils UK with Custom Oligonucleotides"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Integrated DNA Technologies (IDT) has signed a three year contract with Research Councils UK (RCUK) for the supply of synthetic oligonucleotides.

RCUK coordinates the UK’s seven research councils, enhancing the overall impact and effectiveness of the research they fund. As one of the preferred suppliers of custom oligonucleotides, IDT’s expert production technologies will aid RCUK in delivering on the UK government’s objectives for science and innovation.

Each year RCUK invests approximately £2.5 billion in research, covering a broad spectrum of academic disciplines from medical and biological sciences, to astronomy, physics and chemistry. “We are delighted to name IDT as one of our preferred suppliers of custom oligonucleotides” commented Richard Fowles, Category Manager, RCUK. He continued, “IDT’s advanced manufacturing capabilities will provide the scientists we fund with a broad range of synthetic oligos to cover all of their requirements.”

“It is fantastic news that we have been selected as a preferred supplier by RCUK. We want researchers in the UK to benefit from IDT’s twenty-year commitment to tireless innovation and peerless quality in oligo synthesis. We can also use this opportunity to learn how IDT can best support research worldwide, as the science and application of synthetic biology advances,” commented Dr. Joseph A. Walder, IDT’s founder and CEO.